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OBJECTIVES This study was designed to evaluate the relationship between elevated creatinine levels and
cardiovascular events.
BACKGROUND End-stage renal disease is associated with high cardiovascular morbidity and mortality. The
association of mild to moderate renal insufficiency with cardiovascular outcomes remains
unclear.
METHODS We analyzed data from the Cardiovascular Health Study, a prospective population-based
study of subjects, aged 65 years, who had a serum creatinine measured at baseline (n 
5,808) and were followed for a median of 7.3 years. Proportional hazards models were used
to examine the association of creatinine to all-cause mortality and incident cardiovascular
mortality and morbidity. Renal insufficiency was defined as a creatinine level 1.5 mg/dl in
men or 1.3 mg/dl in women.
RESULTS An elevated creatinine level was present in 648 (11.2%) participants. Subjects with elevated
creatinine had higher overall (76.7 vs. 29.5/1,000 years, p  0.001) and cardiovascular (35.8
vs. 13.0/1,000 years, p 0.001) mortality than those with normal creatinine levels. They were
more likely to develop cardiovascular disease (54.0 vs. 31.8/1,000 years, p  0.001), stroke
(21.1 vs. 11.9/1,000 years, p  0.001), congestive heart failure (38.7 vs. 17/1,000 years, p 
0.001), and symptomatic peripheral vascular disease (10.6 vs. 3.5/1,000 years, p  0.001).
After adjusting for cardiovascular risk factors and subclinical disease measures, elevated
creatinine remained a significant predictor of all-cause and cardiovascular mortality, total
cardiovascular disease (CVD), claudication, and congestive heart failure (CHF). A linear
increase in risk was observed with increasing creatinine.
CONCLUSIONS Elevated creatinine levels are common in older adults and are associated with increased risk
of mortality, CVD, and CHF. The increased risk is apparent early in renal disease. (J Am
Coll Cardiol 2003;41:1364–72) © 2003 by the American College of Cardiology Foundation
Individuals with end-stage renal disease have a cardiovas-
cular mortality rate that is 10 to 20 times greater than that
in the general population (1). However, whether milder
degrees of renal insufficiency are an independent predictor
of cardiovascular outcomes is unclear. In several prospective
studies, renal insufficiency, as documented by elevated
creatinine levels, has been associated with an increased risk
of cardiovascular events and mortality (2–5). In other
studies, however, elevated creatinine was no longer an
independent predictor after adjustment for other risk factors
(6). Renal insufficiency is associated with a high prevalence
of traditional cardiovascular risk factors, which may explain
the association with cardiovascular events. Renal insuffi-
ciency may also amplify the severity of these risk factors,
thus promoting cardiovascular risk (7). In addition, renal
insufficiency is associated with higher levels of novel risk
factors, such as C-reactive protein (CRP), homocysteine,
asymmetric dimethylarginine, and fibrinogen (8–10).
The prevalence of renal dysfunction rises with age,
particularly after age 70 (11). The elderly also have the
highest incidence of cardiac events (12) and thus would
experience the greatest burden from both cardiovascular
disease (CVD) and renal disease. The Cardiovascular
Health Study (CHS) is a population-based, longitudinal
study of CVD and stroke in men and women aged 65
years. Previous analyses of CHS have found elevated creat-
inine levels to be among the predictors of total mortality
(13) and congestive heart failure (CHF) (14). This report
investigates in depth the association of elevated creatinine
with cardiovascular events and mortality.
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METHODS
Subjects. The CHS participants were recruited from
Medicare eligibility lists at four locations: Forsyth County,
North Carolina; Sacramento County, California; Washing-
ton County, Maryland; and Pittsburgh, Pennsylvania (15).
They were invited to participate if they were community
dwelling adults over the age of 65, were expected to remain
in the area for the next three years, and were able to give
informed consent without a proxy. There was not an upper
limit of creatinine that defined ineligibility for CHS. The
initial cohort was recruited from 1989 to 1990, and a second
cohort of 687 African Americans was recruited from 1992
to 1993, resulting in a total of 5,888 participants. Baseline
serum creatinine measurements were missing for 80 partic-
ipants (1.4%), so the final sample for this report is 5,808.
The details of the initial exam have been described
elsewhere (15). The baseline examination included inter-
views and questionnaires regarding medical history, medi-
cation use, physical activity, and functional status. Labora-
tory tests were performed after an 8- to 12-h fast. Baseline
cardiovascular status was determined by a review of old
records and by electrocardiogram, echocardiography, carotid
artery ultrasound, and ankle-arm index (15–17).
We defined an elevated creatinine level using a gender-
defined cutoff (1.3 mg/dl for women and 1.5 mg/dl for
men), based on prior studies (4,6). We also categorized
serum creatinine levels as 1.10, 1.10 to 1.29, 1.30 to 1.49,
1.50 to 1.69, and 1.70 mg/dl to evaluate the presence of a
trend with renal dysfunction and cardiovascular risk.
Variables. Detailed methods for blood drawing, quality
assurance, and assay performances have been described
previously (17). Serum chemistries, including creatinine,
were performed on the Kodak Ektachem 700 Analyzer
(Eastman Kodak, Rochester, New York); The Olympus
Demand System (Olympus, Lake Success, New York) was
used for total and high-density lipoprotein (HDL) choles-
terol and triglycerides; low-density lipoprotein (LDL) cho-
lesterol was calculated by the Friedewald formula (18).
Fibrinogen was measured in a BBL fibrometer (Becton
Dickinson, Cockeysville, Maryland); factor VII was per-
formed using Coag-A-Mate (Organon Teknika, Durham,
North Carolina). C-reactive protein was measured using an
enzyme-linked immunosorbent assay (19).
Diabetes was defined as the use of insulin or oral
hypoglycemic agents, a fasting glucose level 140 mg/dl, or
a 2-h glucose level after a 75-g glucose challenge of 200
mg/dl. Impaired glucose tolerance was defined as a fasting
glucose level140 mg/dl but 2-h glucose level between 140
and 199 mg/dl. Prevalent coronary heart disease was defined
as the history of any of the following: reported or silent MI
or angina, previous coronary bypass surgery or angioplasty,
or use of nitrates. Subclinical CVD was defined for subjects
without prevalent CVD at baseline as: ankle-arm index
(AAI) 0.9, common carotid intima-media thickness
(IMT) in upper quintile (1.20 mm), maximum carotid
stenosis 50%, major ECG abnormality (ventricular con-
duction defect, major Q-wave abnormalities, left ventricular
hypertrophy, isolated ST-T wave abnormalities, atrial fibril-
lation, first degree AV block, or left ventricular ejection
fraction borderline or abnormal (20).
Clinical outcomes were ascertained every six months. The
primary endpoints collected were all-cause mortality, car-
diovascular mortality and morbidity (myocardial infarction
[MI], angina, CHF, peripheral vascular disease, stroke, and
transient ischemic attack). Event ascertainment followed a
defined protocol, and events were adjudicated by committee
(21). Cardiovascular disease was defined as any of the
following: reported or silent MI, reported angina, coronary
artery bypass surgery or angioplasty, use of nitrates, stroke,
or transient ischemic attack. The current report examines
events through June 30, 1997. The median follow-up was
7.3 years (mean 6.5, range 0.0 to 8.1).
Statistical analysis. Demographic characteristics, cardio-
vascular risk factors, and subclinical CVD prevalence at
baseline were compared using t test, Kruskal Wallis test, or
chi-square test where appropriate. Event rates were com-
pared with Poisson. For nonfatal events, only time to the
first event was included in the calculation of rates. For the
survival curves, we fitted a Cox proportional hazards model
and plotted predicted survival at the average predictor,
adjusting for age within the model. Cox proportional
hazards models were used to examine the relationship of
creatinine with total mortality and each of the cardiovascular
outcomes. The main focus was on incident CVD events.
Therefore, for these analyses, those with a prior history of
the event were excluded. In order to examine subjects with
prevalent disease at baseline, we examined the first recurrent
MI or cerebrovascular accident event in subjects who had
prior MI or cerebrovascular accident. The whole CHS
sample was used to evaluate mortality outcomes. Multivar-
iate analysis was conducted to determine the independent
association of creatinine categories with each outcome. A
backwards stepwise model was used (subject to p  0.2).
The relationship of creatinine with outcomes was nonlinear.
Creatinine was categorized and forced into the model.
As renal impairment and CVD rise with age, the initial
model was age-adjusted. The second model adjusted for age
Abbreviations and Acronyms
AAI  ankle-arm index
CHF  congestive heart failure
CHS  Cardiovascular Health Study
CI  confidence interval
CRP  C-reactive protein
CVD  cardiovascular disease
HDL  high-density lipoprotein
HR  hazards ratio
IMT  intima-media thickness
LDL  low-density lipoprotein
MI  myocardial infarction
1365JACC Vol. 41, No. 8, 2003 Fried et al.
April 16, 2003:1364–72 Renal Insufficiency as a Predictor of CVD
and subclinical cardiovascular variables (AAI, common
carotid IMT, maximum carotid stenosis, major electrocar-
diographic abnormalities [yes/no], and left ventricular ejec-
tion fraction) to determine the extent to which prevalent
vascular disease confounded the association of creatinine
levels with CVD. Ankle-arm index and common carotid
IMT were entered as continuous variables. Maximum
carotid stenosis was classified as none, 1% to 24%, 25% to
49%, 50% to 74%, 75% to 99%, and 100%. Left ventricular
ejection fraction was classified as normal, borderline, or
abnormal.
The third model included age, gender, race, physical
activity, LDL cholesterol, HDL cholesterol, triglycerides,
systolic and diastolic blood pressure, diabetes, smoking
status, fibrinogen, factor VII, aspirin use, and CRP. Lipid
values, systolic and diastolic blood pressure, fibrinogen,
factor VII, and CRP values were entered as continuous
variables. The fourth model adjusted for all the above
demographic, comorbidity, biochemical, and vascular dis-
ease measures. Interactions of creatinine with gender, dia-
betes, and race were examined.
STATA Statistical Software, Release 7.0 (Stata Corpo-
ration, Inc., College Station, Texas) was used for the
analyses. A p value 0.05 was considered statistically
significant. Confidence intervals (CI) are expressed as 95%
CI.
RESULTS
The number of participants in CHS who had elevated
creatinine was 648 (11.2%) at baseline, as defined by a
serum creatinine 1.3 mg/dl for women and 1.5 mg/dl
for men. The mean serum creatinine was 1.2  0.4 mg/dl
(range 0.6 to 10.0) in men and 0.9  0.3 mg/dl (range 0.4
to 7.3) in women. The characteristics of those with and
without an elevated creatinine are summarized in Table 1.
Those with an elevated creatinine were older, more likely to
smoke, and had higher levels of inflammatory and prothrom-
botic markers. Low-density lipoprotein cholesterol levels in
both groups were similar, but participants with elevated creat-
inine had higher triglycerides and lower HDL levels. Those
with elevated creatinine had a higher prevalence at baseline of
clinical and subclinical CVD; 278 (42.9%) of people with an
elevated creatinine had prevalent disease at baseline compared
with 1,200 (23.2%) of people without (p  0.0001). The
prevalence of subclinical disease was 446 (68.8%) among
Table 1. Baseline Characteristics of Cardiovascular Health Study Participants With and Without Gender-Specific Creatinine
Elevation*
Variable
Creatinine Normal (n  6160) Creatinine Elevated (n  648)
p Valuen (%) Mean  SD n (%) Mean  SD
Age (yrs) 72.5  5.4 75.7  6.5  0.001
Race 0.06
White 4,358 (84.5) 537 (82.9)
Black 769 (14.9) 107 (16.5)
Other 33 (0.6) 4 (0.6)
Gender  0.001
Male 2,077 (40.3) 394 (60.8)
Female 3,083 (59.7) 254 (39.2)
Diabetes status 0.007
Normal 3,660 (70.9) 425 (65.6)
Impaired fasting glucose 696 (13.5) 90 (13.9)
Diabetes 804 (15.6) 133 (20.5)
Systolic BP (supine, mm Hg) 139.4  20.3 144.0  22.2  0.001
Diastolic BP (supine, mm Hg) 70.8  11.9 71.8  12.2 0.05
LDL (adjusted, mg/dl) 127.8  35.4 126.8  38.9 0.52
HDL (mg/dl) 54.9  15.7 48.6  14.7  0.001‡
Triglycerides (mg/dl) 137.9  76.3 153.7  80.8  0.001‡
Lipoprotein(a)† (mg/dl) 53.3  56.3 58.2  51.2  0.001‡
C-reactive protein (g/dl) 3.5  6.0 5.1  8.2  0.001‡
Albumin (g/dl) 4.0  0.3 4.0  0.3 0.22
Fibrinogen (mg/dl) 321.3  66.2 344.5  71.8  0.001
Factor VII (mg/dl) 122.6  28.8 130.3  34.1  0.001
Factor VIII† (mg/dl) 120.4  36.3 138.1  42.2  0.001
Smoking status 0.14
Never 2,409 (46.7) 282 (43.5)
Former 2,136 (41.4) 285 (44.0)
Current 609 (11.8) 81 (12.5)
Smoking pack-years 17.4  26.4 22.4  30.6 0.001
Physical activity (kcals) 1,774  2,062 1274  1723  0.001‡
Aspirin 178 (3.5) 40 (6.2)  0.001
* 1.5 mg/dl for men or 1.3 mg/dl for women; †not available for African-American cohort; ‡analyzed with Kruskal-Wallis test.
BP  blood pressure; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
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individuals with elevated creatinine levels versus 2,260 (43.8%)
of those without elevated creatinine (p  0.001).
Subjects with elevated creatinine had higher all-cause
(76.7 vs. 29.5/1,000 years, p  0.001) and cardiovascular
(35.8 vs. 13.0/1,000 years, p  0.001) mortality and were
more likely to develop incident CVD (54.0 vs. 31.8/1,000
years, p  0.001), MI (18.4 vs. 11.6/1,000 years, p 
0.001), stroke (21.1 vs. 11.9/1,000 years, p 0.001), angina
(31.5 vs. 20.1/1,000 years, p  0.001), CHF (38.7 vs.
17.0/1,000 years, p  0.001), or claudication (10.6 vs.
3.5/1,000 years, p  0.001). Figure 1 shows the age-
adjusted survival curve for all-cause mortality by creatinine
level. The rates of events by level of creatinine are shown in
Table 2.
The risk of mortality, CVD, and CHF increased steadily
with increased creatinine levels (Table 3). Adjustment for
cardiovascular risk factors and subclinical vascular disease
decreased the relative risks somewhat. However, creatinine
levels remained significantly associated with all-cause mor-
tality, cardiovascular mortality, noncardiovascular mortality,
CVD, and CHF. Table 4 shows the detailed results of the
final model for cardiovascular mortality. Elevated creatinine
was associated with a similar risk of death as other cardio-
vascular risk factors, such as smoking and diabetes. We
Figure 1. Age-adjusted survival of subjects in Cardiovascular Health Study (CHS), by serum creatinine (mg/dl).
Table 2. Incidence of Selected Outcomes in Cardiovascular Health Study Participants by Creatinine Level
Outcome
Creatinine Levels (mg/dl)
<1.10 1.10–1.29 1.30–1.49 1.50–1.69 >1.70
Rate/1,000 yrs Rate/1,000 yrs Rate/1,000 yrs Rate/1,000 yrs Rate/1,000 yrs
All-cause mortality 26.2 38.4 55.6 85.3 121.6
CVD death 11.3 17.6 28.6 34.5 57.2
Non-CVD death 14.9 20.7 27.1 50.8 64.4
CHD, stroke, or TIA 29.6 38.2 50.9 62.2 73.3
Congestive heart failure 15.4 21.7 29.2 43.7 59.0
Myocardial infarction 10.3 14.6 20.2 19.4 24.4
Angina 17.9 26.4 31.5 35.3 40.1
Claudication 3.0 4.4 9.8 10.7 14.7
Stroke 10.9 15.2 15.8 26.0 33.1
TIA 2.7 5.3 5.5 3.2 11.4
CHD  coronary heart disease; CVD  cardiovascular disease; TIA  transient ischemic attack.
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Table 3. Hazard Ratios and 95% CIs for Association Between Baseline Serum Creatinine and Incident Cardiovascular Outcomes
Model
Serum Creatinine, mg/dl
<1.10
(n  3,980)
1.10–1.29
(n  1,040)
HR (95% CI)
1.30–1.49
(n  438)
HR (95% CI)
1.50–1.69
(n  180)
HR (95% CI)
>1.70
(n  170)
HR (95% CI)
All-cause mortality
Age-adjusted model 1.00 1.26 (1.09–1.46) 1.75 (1.47–2.10) 2.54 (2.02–3.20) 3.24 (2.62–4.02)
Subclinical variables and age 1.00 1.12 (0.97–1.30) 1.50 (1.25–1.80) 1.83 (1.43–2.33) 2.16 (1.73–2.71)
Traditional risk factors 1.00 1.07 (0.91–1.26) 1.40 (1.15–1.71) 1.71 (1.33–2.21) 2.25 (1.76–2.87)
All above variables 1.00 0.98 (0.83–1.16) 1.27 (1.04–1.56) 1.42 (1.09–1.85) 1.71 (1.33–2.20)
CVD death
Age-adjusted model 1.00 1.36 (1.10–1.69) 2.13 (1.65–2.74) 2.45 (1.71–3.50) 3.67 (2.69–5.02)
Subclinical variables and age 1.00 1.10 (0.88–1.38) 1.62 (1.25–2.10) 1.45 (0.99–2.12) 1.90 (1.36–2.65)
Traditional risk factors 1.00 1.13 (0.89–1.44) 1.63 (1.23–2.16) 1.52 (1.03–2.26) 2.44 (1.72–3.47)
All above variables 1.00 0.99 (0.77–1.27) 1.40 (1.05–1.86) 1.16 (0.78–1.74) 1.63 (1.13–2.33)
Non-CVD death
Age-adjusted model 1.00 1.18 (0.97–1.43) 1.48 (1.15–1.90) 2.60 (1.93–3.51) 2.93 (2.19–3.92)
Subclinical variables and age 1.00 1.12 (0.92–1.37) 1.40 (1.08–1.81) 2.18 (1.59–2.98) 2.39 (1.76–3.26)
Traditional risk factors 1.00 1.00 (0.81–1.25) 1.19 (0.90–1.57) 1.83 (1.31–2.54) 1.98 (1.42–2.76)
All above variables 1.00 0.97 (0.78–1.22) 1.15 (0.87–1.53) 1.66 (1.18–2.34) 1.74 (1.23–2.46)
CVD
Age-adjusted model 1.00 1.32 (1.19–1.45) 1.72 (1.51–1.95) 2.13 (1.77–2.56) 2.80 (2.34–3.36)
Subclinical variables and age 1.00 1.15 (1.03–1.29) 1.44 (1.25–1.66) 1.83 (1.47–2.26) 1.76 (1.43–2.16)
Traditional risk factors 1.00 1.13 (1.01–1.26) 1.28 (1.11–1.48) 1.48 (1.21–1.81) 2.03 (1.66–2.49)
All above variables 1.00 1.03 (0.91–1.16) 1.19 (1.02–1.39) 1.44 (1.14–1.82) 1.54 (1.23–1.94)
Congestive heart failure
Age-adjusted model 1.00 1.26 (1.04–1.53) 1.62 (1.26–2.08) 2.47 (1.77–3.44) 3.04 (2.21–4.19)
Subclinical variables and age 1.00 1.15 (0.94–1.40) 1.37 (1.06–1.76) 1.80 (1.26–2.56) 2.12 (1.51–2.98)
Traditional risk factors 1.00 1.17 (0.94–1.46) 1.37 (1.04–1.81) 1.82 (1.27–2.60) 2.40 (1.68–3.43)
All above variables 1.00 1.13 (0.91–1.41) 1.27 (0.96–1.68) 1.48 (1.01–2.15) 1.92 (1.32–2.80)
Variables were selected using backward stepwise procedure with p  0.2 as criterion for exclusion. Subclinical and age model was adjusted for age, ankle-arm index, common
carotid intima-media thickness, maximum carotid stenosis (none, 1% to 24%, 25% to 49%, 50% to 74%, 75% to 99%, 100%), major electrocardiographic abnormalities (yes, no),
and left ventricular ejection fraction (normal, borderline, abnormal). Traditional risk factor model was adjusted for the following baseline variables: age, gender, race, physical
activity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure, diabetes, smoking status,
fibrinogen, factor VII, C-reactive protein, hemoglobin, and aspirin use.
CI  confidence interval; CVD  cardiovascular disease; HR  hazard ratio.
Table 4. Characteristics Associated With Cardiovascular Mortality in Elderly Participants of the
Cardiovascular Health Study
Variable* HR 95% CI p Value
Age 1.07 1.06–1.09  0.001
Ankle-arm index 0.28 0.17–0.44  0.001
Common carotid intima-medial thickness 2.01 1.38–2.95  0.001
Maximum carotid stenosis 1.22 1.09–1.37  0.001
Major electrocardiogram abnormalities 1.84 1.50–2.26  0.001
Left ventricular ejection fraction 1.68 1.45–1.94  0.001
Gender (men) 1.19 0.93–1.52 0.172
Diabetes 1.47 1.31–1.65  0.001
Smoking 1.18 1.02–1.38 0.030
Diastolic blood pressure (1 mm Hg) 1.01 1.00–1.02 0.063
Fibrinogen (1 mg/dl) 1.002 1.000–1.003 0.033
Creatinine (mg/dl) 0.001
1.1 1.0 (reference)
1.1–1.29 0.99 0.77–1.27
1.3–1.49 1.40 1.05–1.86
1.5–1.69 1.16 0.78–1.74
1.7 mg/dl 1.63 1.13–2.33
*Variables were selected using backward stepwise procedure with p  0.2 as criterion for exclusion. Variables were creatinine,
age, ankle-arm index, common carotid intima-media thickness. maximum carotid stenosis (none, 1% to 24%, 25% to 49%, 50%
to 74%, 75% to 99%, 100%), major electrocardiographic abnormalities (yes, no), left ventricular ejection fraction (normal,
borderline, abnormal), gender, race, physical activity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol,
triglycerides, systolic blood pressure, diastolic blood pressure, diabetes, smoking status, fibrinogen, factor VII, C-reactive protein,
hemoglobin, and aspirin use.
CI  confidence interval; HR  hazard ratio.
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performed a subgroup analysis in individuals with and
without significant subclinical disease. There was a linear
relationship of elevated creatinine levels with CVD mortal-
ity in those with subclinical disease. In those without
significant subclinical disease (n  3,122), the only signif-
icant risk factors were age, diabetes, and a creatinine level
1.7 mg/dl.
We found no evidence for a center effect, nor did we
observe any significant gender, race, or diabetes interactions
with creatinine levels. However, in the unadjusted models
for all-cause mortality, cardiovascular mortality, and CHF,
the risk began at a lower serum creatinine level for women
compared with men (Table 5). With adjustment, the risks
were similar for men and women. We evaluated the asso-
ciation of creatinine levels with the incidence of each
cardiovascular outcome, using the dichotomized gender-
based cutoff to define elevated creatinine. An elevated
creatinine level was associated with each individual outcome
in the univariate analysis. However, after multivariate anal-
ysis, we no longer found significant associations with MI
(hazard ratio [HR] 1.00, 95% CI 0.74, 1.36), angina (HR
1.12, 95% CI 0.87, 1.43), stroke (HR 1.22, 95% CI 0.93,
1.61) and transient ischemic attack (HR 1.39, 95% CI 0.84,
2.29). Elevated creatinine remained a significant predictor
for the development of claudication (HR 1.61, 95% CI 1.05,
2.49), but we found a significant gender interaction. After
multivariate adjustment, the HR for men was 1.38 (0.78,
2.43) and for women was 2.29 (1.11, 4.73).
There were 159 recurrent MIs and 141 recurrent strokes.
Patients with elevated creatinine were more likely to have
recurrent events. After adjustment for risk factors and
subclinical disease, there was no longer a significant rela-
tionship with recurrent MI, but we still observed a linear
trend of increasing risk for recurrent stroke with increasing
creatinine (Table 6).
DISCUSSION
We found that elderly individuals with mildly elevated
serum creatinine levels had a greater incidence of cardiovas-
cular events and mortality compared with other elderly
individuals with normal creatinine levels. The value of
elevated creatinine levels in predicting the development of
CHF, CVD morbidity and mortality, and all-cause mortal-
ity remained after adjustment for many cardiovascular risk
factors and subclinical disease measures. That the increased
risk of death began at low creatinine levels in our study is
noteworthy, as the values are near or below the normal value
for many laboratories. Many physicians and patients may
not, therefore, recognize the increased risk associated with
mildly elevated creatinine.
Hemmelgram et al. (22) found that elevated creatinine
predicted poor long-term survival in patients undergoing
coronary angiography. Mildly to moderately elevated creat-
inine levels are a risk factor for adverse outcomes after
cardiac and noncardiac surgery (23,24). However, these Ta
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findings may not be generalizable to other populations. In
the Framingham study, Culleton et al. (6) found that
all-cause mortality was higher than in men with normal
creatinine levels. In contrast to our study, however, they did
not find that it was a risk factor in women, once they
adjusted for age and cardiac risk factors. A recent analysis of
the NHANES 2 follow-up data found that those with renal
insufficiency had a higher total and cardiovascular mortality
rate, after controlling for traditional risk factors (3). They
did not have data on nonfatal events or on subclinical
disease measurements.
The reasons mild elevation of creatinine is associated with
adverse outcomes are not clear. Some risk factors, such as an
elevated calcium-phosphorus product, which could promote
vascular calcification, do not appear to increase until the
glomerular filtration rate is 30 ml/min (25). A possible
explanation is that persons with renal insufficiency have
greater atherosclerosis burden. However, despite adjustment
for several measures of subclinical atherosclerosis, a greater
cardiovascular risk remained associated with elevated creat-
inine levels. Though elevated creatinine was a predictor of
CVD as a combined outcome, for many of the individual
cardiovascular outcomes, it was no longer an independent
predictor after adjustment for other risk factors. It could be
that elevated creatinine is a marker of the presence of
multiple metabolic abnormalities and that the unexplained
risk associated with an elevated creatinine level is due to
other factors that were not measured. In particular, we do
not have data on proteinuria. In the HOPE trial (2),
microalbuminuria was a significant risk factor for CVD
events, which was independent of an elevated creatinine
level or history of diabetes.
Many of the features associated with renal insufficiency
are similar to those described in the metabolic syndrome:
hypertension, high triglyceride levels, and low HDL cho-
lesterol. This syndrome has also been associated with
increased cardiovascular risk (26). Like the metabolic syn-
drome (27,28), elevated creatinine levels have been associ-
ated with small dense LDL and hyperfibrinogenemia
(29,30). Elevated creatinine levels may not be merely a
marker of atherosclerosis and increased prevalence of risk
factors. Renal disease could also worsen the severity of risk
factors, such as hypertension and hyperlipidemia (7). If this
hypothesis is true, risk factors would be mediators of the
increased risk and could explain why elevated creatinine was
no longer a predictor for MI or stroke after adjustment. We
do not have longitudinal data on the change in risk factors
with the change in creatinine to test this hypothesis.
The kidney is the site of metabolism of many molecules.
Chronic renal insufficiency is associated with higher levels of
inflammatory markers and homocysteine (10,31–33), which
have been associated with cardiovascular events (34–36).
Cytokines have been implicated in the pathogenesis of heart
failure (37,38). This may be one explanation for why
elevated creatinine was a predictor of CHF in our study.
Anemia is a common feature of renal disease, as the kidney
is the site of erythropoietin synthesis. Levin et al. (39) found
that a decline in hemoglobin and an increase in systolic
blood pressure predicted an increase in left ventricular mass
index in persons with chronic kidney disease, which may be
a precursor to the development of heart failure. In our study,
we controlled for CRP, systolic blood pressure, and hemo-
globin. Elevated creatinine remained an independent pre-
dictor of CHF after controlling for these factors.
Study limitations. Muscle mass tends to decline with age.
Therefore, a creatinine level of 1.5 mg/dl in a 75-year-old
does not represent the same degree of renal impairment as
it does in a 55-year-old (40). A limitation of our study is the
lack of more precise measurements of renal function. More
precise methods, such as iothalamate clearances, are difficult
and expensive to do in large epidemiologic studies, and 24-h
creatinine clearances are unreliable (41). The Modification
of Diet in Renal Disease formulas, which have been
advocated as a more accurate measure of renal function,
have not been validated in the elderly (42). Serum creatinine
has the advantage of being widely available and a common
Table 6. Hazard Ratios and 95% CIs for Association Between Baseline Serum Creatinine and First Recurrent MI and
Cerebrovascular Accidents
Model
Serum Creatinine, mg/dl
<1.10
(n  3,980)
1.10–1.29
(n  1,040)
HR (95% CI)
1.30–1.49
(n  438)
HR (95% CI)
1.50–1.69
(n  180)
HR (95% CI)
>1.70
(n  170)
HR (95% CI)
Recurrent MI
Age-adjusted model 1.00 1.97 (1.34–2.90) 2.85 (1.78–4.56) 2.36 (1.09–5.15) 5.52 (3.02–10.08)
Traditional risk factors* 1.00 1.58 (1.02–2.43) 1.74 (1.03–2.93) 1.37 (0.61–3.08) 2.97 (1.51–5.86)
Traditional risk factors and subclinical disease* 1.00 1.27 (0.80–2.03) 1.54 (0.89–2.64) 1.31 (0.58–2.98) 1.56 (0.73–3.36)
Recurrent stroke
Age-adjusted model 1.00 1.29 (0.82–2.03) 2.26 (1.34–3.80) 3.37 (1.73–6.56) 5.73 (3.17–10.34)
Traditional risk factors 1.00 1.10 (0.66–1.83) 1.60 (0.89–2.89) 2.01 (0.96–4.21) 3.53 (1.81–6.88)
Traditional risk factors and subclinical disease 1.00 0.85 (0.47–1.53) 1.32 (0.69–2.51) 1.56 (0.67–3.60) 2.22 (1.03–4.82)
*Variables were selected using backward stepwise procedure with p  0.2 as criterion for exclusion. Traditional risk factor model was adjusted for the following baseline variables:
age, gender, race, physical activity, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure, diabetes,
smoking status, fibrinogen, factor VII, C-reactive protein, hemoglobin, and aspirin use. Traditional risk factors and subclinical disease was adjusted for the traditional risk factors
plus ankle-arm index, common carotid intima-media thickness, maximum carotid stenosis (none, 1% to 24%, 25% to 49%, 50% to 74%, 75% to 99%, 100%), major
electrocardiographic abnormalities (yes, no), and left ventricular ejection fraction (normal, borderline, abnormal).
CI  confidence interval; HR  hazard ratio; MI  myocardial infarction.
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part of routine chemistry panels. It would, therefore, be
relatively easy to use as a screening test for identifying
patients at increased risk.
Conclusions. More than 10% of our cohort had elevated
serum creatinine levels, defined as 1.5 mg/dl in men or
1.3 mg/dl in women. As there is an increased risk of CVD
in individuals with an elevated creatine, this implies that an
elevated creatinine, defined this way, may have a substantial
attributable risk for CVD and mortality in the elderly
population. As the population ages, the prevalence of renal
insufficiency and CVD may also grow. That elevated creat-
inine is associated with a high prevalence of cardiac risk
factors suggests that attention to risk factor reduction may
impact the high risk of CVD. A recent Canadian study
suggests that cardiac risk factors are inadequately addressed
in patients with renal insufficiency (43). In that study, 35%
of those with renal insufficiency and established CVD had a
blood pressure 140/90 mm Hg; 45% were receiving
aspirin, 50% were receiving beta-blockers and only 50% of
those with hyperlipidemia were on statins. There is a lack of
research on prevention of CVD in individuals with renal
insufficiency. The National Cholesterol Education Program
(NCEP) Adult Treatment Panel III recommended that
diabetes be considered a coronary heart disease equivalent
(44). In a similar fashion, the National Kidney Foundation
Task Force on Cardiovascular Disease recommended that
patients with chronic kidney disease be considered in the
highest risk group for cardiovascular events (45). Although
this recommendation was not adopted by NCEP, our study
supports this recommendation.
In summary, our study found that mildly elevated creat-
inine levels are predictive of cardiovascular morbidity and
mortality. Elevated creatinine was associated with a high
prevalence of cardiac risk factors. Further studies aimed at
risk reduction of traditional and novel risk factors in those
with renal insufficiency are needed in order to have an
impact in this high-risk population.
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